| 影响非小细胞肺癌维持化疗疗效的相关因素探讨 |
| |
| 引用本文： | 庄莉,王清泉.影响非小细胞肺癌维持化疗疗效的相关因素探讨[J].昆明医学院学报,2009,30(6):76-79. |
| |
| 作者姓名： | 庄莉 王清泉 |
| |
| 作者单位： | 昆明医学院第三附属医院,云南省肿瘤医院化疗中心二病区,云南昆明,650118 |
| |
| 摘 要： | 目的探讨影响非小细胞肺癌（NSCLC）维持化疗近期疗效和中位生存期（MST）的相关因素．方法选择68例Ⅲb～Ⅳ期NSCLC患者，均接受初期4个周期的诱导化疗且达到完全缓解和部分缓解患者．随机分为治疗组与对照组，治疗组给予维持治疗，对照组给予最佳支持治疗．治疗2个周期以上评价疗效，计算中位生存期，测定外周血白细胞（WBC）、血红蛋白（HB）、血小板（PLT）的数量和毒副反应的监测．结果治疗组有效率、临床受益率、MST显著高于对照组（P〈0．05）．性别在MST上的未见显著差异（P〉0．05），而在不同的TNM分期、病理和病灶类型上存在明显差异（P〈0．05），DIB期患者的MST显著长于Ⅳ期患者（P〈0．05），鳞癌患者的MST明显长于非鳞癌患者（P〈0．05），小病灶患者的MST明显长于弥漫性病灶和大病灶患者（P〈0．05）．MST与TNM分期、病理类型、病灶类型密切相关，与性别无相关性．结论培美曲塞维持治疗非小细胞肺癌有较好的疗效，且毒性反应轻，耐受性好．TNM分期、病理类型和病灶类型是影响培美曲塞维持治疗NSCLC临床疗效和中位生存时间的主要因素．
|
| 关 键 词： | 维持化疗 非小细胞肺癌 近期疗效 中位生存期 |
Analysis of Survival-Associated Factors on Non-small cell Lung Cancer by Maintenance of Chemotherapy |
| |
| ZHUANG Li,WANG Qing-quan.Analysis of Survival-Associated Factors on Non-small cell Lung Cancer by Maintenance of Chemotherapy[J].Journal of Kunming Medical College,2009,30(6):76-79. |
| |
| Authors: | ZHUANG Li WANG Qing-quan |
| |
| Affiliation: | (The Chemotherapy Centre, The 3rd Affiliated Hospied of Kunming Medical University, Yunnan Tumor Hospital, Kunming Yunnan 650118, China) |
| |
| Abstract: | Objective To study the effects of non-small cell lung cancer （NSCLC） in the near tuture and associated factors of the median survive time （MST） hy maintenance of chemotherapy. Methods 68 cases Ⅲb - Ⅳ period of NSCLC patients were given 2 cycles of induction chemotherapy and achieved complete remission and partial remission. 68 patients were randomly divided into treatment and control groups, patients received maintenance therapy in the treatment group and patients in control group were given the best supportive care. After four treatment cycles, we evaluated the efficacy, calculated median survival time, determinated peripheral white blood cells （WBC）, hemoglobin （HB）, the numberofplatelets （PLT）and monitored toxicity. Results The effective rate, the rate of clinical benefit, MST were significantly higher in treatment group （P 〈 0.05 ）. Gender in MST had no significant difference （P 〉 0.05） , and in different TNM staging, type of pathological and focus there were significant differences （P 〈 0.05）, in patients with squamous cell carcinoma, the MST scales were significantly longer than patients with no squamous cell carcinoma, the difference was significant （P 〈 0.05）. Small lesions in patients with the MST was longer than diffuse lesions and lesions in patients, the difference was significant （P 〈 0.05 ）. MST was closely related with the TNM staging, pathological type, the type of lesion was, while was not related with gender. Conclusion Pemetrexed maintenance therapy in non-small cell lung cancer has better efficacy, less toxicity, and good tolerance. TNM staging, pathological type and lesion type are the main factors influencing NSCLC efficacy and MST. |
| |
| Keywords: | Maintenance of chemotherapy Non-small cell lung cancer Clinical efficacy Mediansurvival time |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
